Articles

Agilent teams with Picometrics Technologies to offer analytical solutions for biopharmaceutical applications

Agilent Technologies Inc. has signed a co-marketing agreement with Picometrics Technologies to provide biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry
Written byLloyd Dunlap
| 3 min read

SANTA CLARA, Calif.—Agilent Technologies Inc. has signed a co-marketing agreement with Picometrics Technologies to provide biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry.

In addition to classic CE-LIF analysis technology, this collection of tools provides the only online CE-LIF-MS solution available today, the company stated in a news release. The platform’s principal application is for the research and development of complex large-molecule biopharmaceutical compounds.

“We are very pleased to extend a long-standing and fruitful partnership with Agilent and consolidate our development strategy,” said Jean Charles Garcia, president of Picometrics. “This unique technological platform using our new-generation LIF detection will significantly increase efficiency for biotherapeutic characterization in research, development and quality control.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue